- Home
- SCNI vs ONCO Comparison
SCNI vs ONCO Comparison
Compare SCNI & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- ONCO
- Stock Information
- Founded
- SCNI 2003
- ONCO 2018
- Country
- SCNI Israel
- ONCO United States
- Employees
- SCNI N/A
- ONCO N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- ONCO Health Care
- Exchange
- SCNI Nasdaq
- ONCO Nasdaq
- Market Cap
- SCNI 1.9M
- ONCO 1.8M
- IPO Year
- SCNI N/A
- ONCO 2022
- Fundamental
- Price
- SCNI $2.91
- ONCO $0.08
- Analyst Decision
- SCNI
- ONCO
- Analyst Count
- SCNI 0
- ONCO 0
- Target Price
- SCNI N/A
- ONCO N/A
- AVG Volume (30 Days)
- SCNI 15.6K
- ONCO 45.0M
- Earning Date
- SCNI 05-07-2025
- ONCO 05-27-2025
- Dividend Yield
- SCNI N/A
- ONCO N/A
- EPS Growth
- SCNI N/A
- ONCO N/A
- EPS
- SCNI N/A
- ONCO N/A
- Revenue
- SCNI $658,000.00
- ONCO $1,870,605.00
- Revenue This Year
- SCNI N/A
- ONCO N/A
- Revenue Next Year
- SCNI N/A
- ONCO N/A
- P/E Ratio
- SCNI N/A
- ONCO N/A
- Revenue Growth
- SCNI N/A
- ONCO N/A
- 52 Week Low
- SCNI $1.90
- ONCO $0.05
- 52 Week High
- SCNI $8.92
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- SCNI 60.01
- ONCO 49.99
- Support Level
- SCNI $2.66
- ONCO $0.07
- Resistance Level
- SCNI $2.96
- ONCO $0.18
- Average True Range (ATR)
- SCNI 0.18
- ONCO 0.02
- MACD
- SCNI 0.04
- ONCO 0.01
- Stochastic Oscillator
- SCNI 93.15
- ONCO 21.48
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.